For the roughly 70% of breast cancers that are estrogen receptor-positive, tamoxifen has been a cornerstone therapy for decades — yet outcomes vary substantially among patients who appear biologically similar. New evidence suggests that what surrounds a tumor, not just what's inside it, may be a key predictor of who actually benefits from long-term hormonal treatment.
Drawing on transcriptomic data from 513 postmenopausal women enrolled in the Stockholm Tamoxifen (STO-3) randomized trial — a dataset comparing tamoxifen to no endocrine therapy in lymph node-negative, ER+/HER2- breast cancer — researchers applied the ConsensusTME deconvolution algorithm to estimate the relative abundance of 18 distinct immune and stromal cell populations. Patients were stratified into tertiles based on composite immune, fibroblast, and endothelial scores. A striking inverse relationship emerged: lower immune cell abundance in the tumor microenvironment correlated significantly with higher estrogen receptor expression. Critically, tamoxifen-treated patients with low immune scores demonstrated improved distant recurrence outcomes, while those with high immune infiltration appeared to derive comparatively less benefit from the drug — findings that held after multivariable adjustment for tumor grade, size, Ki-67, and progesterone receptor status.
This analysis sits within a growing body of work repositioning the tumor microenvironment from passive backdrop to active determinant of therapy response. The observation that immune-cold tumors — which tend to be more ER-rich — respond preferentially to tamoxifen is mechanistically plausible: dense immune infiltration may signal stromal remodeling pathways that partially circumvent ER-driven proliferation. That said, this is a secondary, exploratory analysis of a historical trial, and transcriptomic deconvolution from bulk tissue carries inherent resolution limits compared to single-cell approaches. The cohort of 513, while meaningful for a secondary analysis, limits statistical power for subgroup conclusions. Still, if validated prospectively, immune scoring at diagnosis could refine endocrine therapy sequencing decisions — an incremental but clinically actionable advance in precision oncology.